about
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma.New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases.Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.An early lesson.Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma.Immunotherapy in surgically resectable non-small cell lung cancer.Association of transforming growth factor-beta1 gene polymorphism with reflux nephropathy.DLL3: an emerging target in small cell lung cancer.Favorable and Durable Response to Pazopanib in Metastatic Refractory ParagangliomaFrequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersReply to J. Delyon et alDo toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the ColonIncidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung CancerImmune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseKRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid CancerHomologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancerChange in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancersResumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated ColitisMetastatic Adrenocortical Carcinoma: a Single Institutional Experience
P50
Q36356699-598E7B63-0F61-4AE7-AE9D-B404B4FB3333Q41807487-4BBDF66F-236E-416D-ADAA-19AAF2C1CDC6Q42318799-2D9093E5-2355-4C89-BA47-0540E88B9EC6Q47270129-7BD9E862-E5C1-477F-8C90-4D7CEBC86E4DQ47558771-76A14548-0084-4C18-B5FD-A7E6E3A023BFQ48343261-D79B0671-CF21-48FF-A95D-0B88369CBEB4Q52558663-C98F5424-60A0-48B6-8A54-F4B0E14C2E75Q52624364-986B3A37-A5B0-4D42-9B79-04696FB66AB2Q54644721-5B6307E3-6DFF-4321-A419-E08005104106Q64981304-B7412539-77D5-4641-963B-1CC1B9FBF727Q88866317-FBB1AFF1-B517-4DBA-9AD5-1740799DC722Q90290457-242F9327-B1A6-4949-B64D-C89DC40BFCBEQ90609398-DDEE991F-02BC-4D8A-86B2-9C744CDD19D5Q90991420-10260C51-3793-4C0A-B3F2-05E7EF414D15Q91288869-DD493D2D-0E59-4F85-A98A-C166915A9CFFQ91346309-05BC5DAE-A6B6-45B2-AFA8-8E467C08CB4CQ91684179-4709D0D0-ADC3-481E-8CA3-ABD20C677797Q91996944-BAC3C711-F3EF-4524-94F1-FAF91C58B0E1Q91997873-6D996AF3-00C0-47C6-A682-DFA1908706BFQ92328146-F9DCDBF2-4395-4C79-B1E0-BA4B34709058Q92515593-86EF00D8-CEF3-4540-AB3E-C4DD5BE1A108Q93003588-D7F62838-8EF8-43DB-B306-C71EFFE88DDE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dwight Owen
@ast
Dwight Owen
@en
Dwight Owen
@es
Dwight Owen
@nl
Dwight Owen
@sl
type
label
Dwight Owen
@ast
Dwight Owen
@en
Dwight Owen
@es
Dwight Owen
@nl
Dwight Owen
@sl
prefLabel
Dwight Owen
@ast
Dwight Owen
@en
Dwight Owen
@es
Dwight Owen
@nl
Dwight Owen
@sl
P106
P1153
57193453886
P21
P31
P496
0000-0002-6598-4886
P569
2000-01-01T00:00:00Z